Abbott reported second-quarter Diagnostics sales grew 42% to $3.09 billion, attributing the jump largely to its acquisition of Exact Sciences earlier in March. The company also disclosed higher cancer diagnostics sales beginning in 2026, reflecting the integration of Exact’s assets into Abbott’s reporting structure. Abbott’s Q2 overall sales rose to $12.59 billion and adjusted EPS beat analysts’ expectations, while management reiterated full-year 2026 guidance and outlined a Q3 adjusted EPS range. For diagnostics investors, the numbers provide a near-term proof point on how consolidation can re-shape segment growth profiles and shift revenue mix toward cancer testing categories.